The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis ; volume:24 ; number:1 ; day:5 ; month:7 ; year:2024 ; pages:1-12 ; date:12.2024
Clinical and experimental medicine ; 24, Heft 1 (5.7.2024), 1-12, 12.2024
- Creator
-
Tong, Zhenhua
Xu, Zhumeng
Duan, Yaqi
Sun, Xue
Qi, Bin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10238-024-01391-3
- URN
-
urn:nbn:de:101:1-2409232122099.204607208708
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
10.06.20252025, 9:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tong, Zhenhua
- Xu, Zhumeng
- Duan, Yaqi
- Sun, Xue
- Qi, Bin
- SpringerLink (Online service)
Other Objects (12)
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
Role of circulating endothelial progenitors in responsiveness to erythropoiesis-stimulating agents in hemodialysis patients
Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial
In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
Serum trace metal association with response to erythropoiesis stimulating agents in incident and prevalent hemodialysis patients
Tips for erythropoiesis-stimulating agent treatment of renal anemia
Correction to: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
Role of circulating endothelial progenitors in responsiveness to erythropoiesis-stimulating agents in hemodialysis patients
Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial
In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
Serum trace metal association with response to erythropoiesis stimulating agents in incident and prevalent hemodialysis patients
Tips for erythropoiesis-stimulating agent treatment of renal anemia
Correction to: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
Role of circulating endothelial progenitors in responsiveness to erythropoiesis-stimulating agents in hemodialysis patients
Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial
In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
Serum trace metal association with response to erythropoiesis stimulating agents in incident and prevalent hemodialysis patients
Tips for erythropoiesis-stimulating agent treatment of renal anemia